| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
- |
| Employees |
71 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-173 |
| Cash Flow (TTM) (Millions $) |
157 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Larimar Therapeutics Inc. is a clinical-stage biotechnology company that was founded in 2018 and is headquartered in Philadelphia, Pennsylvania. The company is focused on developing novel treatments for complex rare diseases, with a particular focus on disorders that affect metabolism or the central nervous system.
Larimar Therapeutics is committed to addressing the significant unmet medical needs in rare diseases that currently have limited or no treatment options. To achieve this goal, the company employs a range of strategies, including gene therapy, protein replacement therapy, and small molecule therapeutics. Larimar's approach is to target specific genetic defects or mutations that underlie rare diseases and to develop treatments that address these underlying causes.
The company's flagship product candidate is CTI-1601, a recombinant fusion protein that is designed to replace the missing enzyme in patients with cystinosis, a rare metabolic disorder. CTI-1601 has received orphan drug designation from the FDA and European Medicines Agency, and the company is currently conducting a Phase I/II clinical trial to evaluate its safety and efficacy in cystinosis patients.
In addition to CTI-1601, Larimar Therapeutics is also developing a pipeline of other product candidates for rare diseases. These include small molecule therapies for Friedreich's ataxia and Niemann-Pick disease type C, as well as gene therapy for Pelizaeus-Merzbacher disease and GM1 gangliosidosis.
Larimar Therapeutics is a publicly traded company on the NASDAQ exchange under the ticker symbol "LRMR." The company has attracted significant attention from investors due to its innovative approach to treating rare diseases and its potential to transform the lives of patients with limited treatment options. The current market capitalization of the company is around $450 million.
Company Address: Three Bala Plaza East Bala Cynwyd 19004 PA
Company Phone Number: 511-9056 Stock Exchange / Ticker: NASDAQ LRMR
|
0.23%